신경아세포종 시장 규모는 향후 수년간 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 5.7%의 연평균 복합 성장률(CAGR)로 39억 3,000만 달러에 달할 것으로 예측됩니다. 예측 기간 중 예상되는 성장은 정부 보조금 증가, 유병률 증가, 조기 발견에 대한 중요성 증가, 유전자 변이 유병률 증가, 연구 및 이해의 진전 등의 요인에 기인합니다. 이 기간 중 예상되는 주요 동향으로는 특정 분자 경로를 표적으로 하는 약물의 개발, 비침습적 영상 기술의 혁신, 유전자 편집 기술의 발전, 개인 맞춤형 치료 접근법에 대한 강조, 방사성 표지 화합물의 개발 등을 들 수 있습니다.
신경아세포종 시장의 성장은 소아암 발병률 증가로 인해 견인될 것으로 예측됩니다. 소아암은 주로 소아 및 청소년이 발병하는 암군을 말하며, 뇌, 혈액, 뼈 등의 장기가 표적이 되는 경우가 많아 특수한 치료법이 필요합니다. 이러한 소아암 환자 증가는 진단 기술의 발전, 인식의 향상, 환경적 노출, 유전적 요인, 의학 연구의 발전 등 여러 가지 요인에 기인합니다. 신경아세포종 치료는 소아암에 대한 표적 치료법을 제공하고 조기 개입을 가능하게 함으로써 젊은 환자의 재발 위험을 줄이고 예후를 개선할 수 있습니다. 예를 들어 2024년 5월 미국 암협회(American Cancer Society)는 2024년 미국에서 15세 미만 소아암 진단을 받는 어린이가 2024년 약 9,620명으로 2023년 5,290명에서 증가할 것으로 예측했습니다. 결과적으로 소아암 발병률 증가는 신경아세포종 시장의 성장을 가속하는 주요 요인으로 작용하고 있습니다.
신경아세포종 시장의 주요 기업은 인간화 항 GD2 모노클로널 항체 등 암세포를 보다 효과적이고 안전하게 표적화할 수 있는 혁신적인 치료법 개발에 주력하고 있습니다. 이러한 항체는 암세포의 GD2 분자를 특이적으로 표적으로 삼도록 설계되는 한편, 인간 성분을 포함시켜 면역 거부반응을 최소화하고 있습니다. 예를 들어 2023년 8월 영국에 본사를 둔 임상 단계의 제약사 르네상스 파마(Renaissance Pharma)는 세인트 주드 아동 연구 병원으로부터 Hu14.18K322A(Hu14.18)를 도입했다고 발표했습니다. 이 항체는 희귀하고 공격성이 높은 소아암인 고위험 신경아세포종과 새로 진단된 소아암 치료를 위해 고안된 항체입니다. 계약에 따르면 르네상스는 미국, 캐나다, 유럽, 중국, 일본, 튀르키예 등 세계 주요 시장에서 Hu14.18을 개발, 제조, 상업화할 수 있는 독점적 권리를 획득했습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 신경아종PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 신경아종 시장 : 성장률 분석
- 세계의 신경아종 시장 실적 : 규모와 성장, 2019-2024
- 세계의 신경아종 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 신경아종 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 신경아종 시장 : 제품 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 정제
- 백신
- 기타 제품 유형
- 세계의 신경아종 시장 : 치료 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 화학요법
- 면역치료
- 기타 치료의 유형
- 세계의 신경아종 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 온라인
- 오프라인
- 세계의 신경아종 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 클리닉
- 세계의 신경아종 시장, 정제의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 경구 화학요법 정제
- 표적 치료 정제
- 세계의 신경아종 시장, 백신의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 면역치료 백신
- 치료 백신
- 세계의 신경아종 시장, 기타 제품 유형의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 주사제
- 모노클로널 항체
- 세포치료 제품
제7장 지역별·국가별 분석
- 세계의 신경아종 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 신경아종 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 신경아종 시장 : 경쟁 구도
- 신경아종 시장 : 기업 개요
- Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- Sartorius AG Overview, Products and Services, Strategy and Financial Analysis
- Recordati S.p.A Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- United Therapeutics Corporation
- BeiGene Ltd.
- MacroGenics Inc.
- Y-mAbs Therapeutics Inc.
- RedHill Biopharma Ltd.
- Clarity Pharmaceuticals Ltd.
- EUSA Pharma(UK) Ltd.
- US WorldMeds LLC
- Healio Inc.
- Ascentage Pharma
- Laboratorio Elea Phoenix S.A
- Curis Inc.
- PersonGen BioTherapeutics(Suzhou) Co. Ltd.
- Essential Pharma S.A
- Cellectar Biosciences Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 신경아종 시장 2029 : 새로운 기회를 제공하는 국가
- 신경아종 시장 2029 : 새로운 기회를 제공하는 부문
- 신경아종 시장 2029 : 성장 전략
제36장 부록
KSA
Neuroblastoma is a type of cancer that predominantly affects children, originating from immature nerve cells called neuroblasts. This cancer often develops in the adrenal glands, which sit atop the kidneys, but it can also occur in other regions of the abdomen, chest, neck, or pelvis. Symptoms associated with neuroblastoma may include abdominal pain, swelling, fatigue, and in some cases, bone pain or the presence of lumps.
The primary product types for treating neuroblastoma include tablets, vaccines, and others. Tablets are solid oral dosages containing active ingredients, binders, and fillers, used in the treatment of neuroblastoma to administer chemotherapy or targeted therapy drugs. Treatment options for neuroblastoma include chemotherapy, immunotherapy, and other approaches, which are distributed through various channels, both online and offline. These treatments are typically used in hospitals and clinics.
The neuroblastoma market research report is one of a series of new reports from The Business Research Company that provides neuroblastoma market statistics including the neuroblastoma industry global market size regional shares competitors with the neuroblastoma market share detailed neuroblastoma market segments market trends and opportunities and any further data you may need to thrive in the neuroblastoma industry. This neuroblastoma market research report delivers a complete perspective of everything you need with an in-depth analysis of the current and future scenarios of the industry.
The neuroblastoma market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.15 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth observed during the historic period can be attributed to factors such as the rising prevalence of neuroblastoma, increased research and development focused on pediatric neuroblastoma treatments, a higher incidence of childhood cancer, and growing government funding and support.
The neuroblastoma market size is expected to see strong growth in the next few years. It will grow to $3.93 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth projected for the forecast period can be attributed to factors such as rising government funding, a higher incidence of the disease, an increasing emphasis on early detection, a growing prevalence of genetic mutations, and advancements in research and understanding. Key trends expected during this period include the development of drugs targeting specific molecular pathways, innovations in non-invasive imaging technologies, progress in gene-editing technologies, a greater focus on personalized treatment approaches, and the development of radiolabeled compounds.
The growth of the neuroblastoma market is expected to be driven by the rising incidence of childhood cancer. Childhood cancer refers to a group of cancers that primarily affect children and adolescents, often targeting organs such as the brain, blood, and bones, and requiring specialized treatment methods. This increase in childhood cancer cases can be attributed to several factors, including advancements in diagnostic techniques, greater awareness, environmental exposures, genetic factors, and progress in medical research. Neuroblastoma treatments offer targeted therapies for childhood cancer, allowing for early intervention that reduces the risk of recurrence and improves the prognosis for young patients. For example, in May 2024, the American Cancer Society, a US-based professional organization, projected that around 9,620 children under the age of 15 in the United States would be diagnosed with cancer in 2024, up from 5,290 cases in 2023. As a result, the rising incidence of childhood cancer is a key factor driving the growth of the neuroblastoma market.
Leading companies in the neuroblastoma market are concentrating on developing innovative therapeutic interventions, such as humanized anti-GD2 monoclonal antibodies, to more effectively and safely target cancer cells. These antibodies are engineered to specifically target the GD2 molecule on cancer cells while minimizing immune rejection by incorporating human components. For example, in August 2023, Renaissance Pharma Ltd., a UK-based clinical-stage pharmaceutical company, announced that it had in-licensed Hu14.18K322A (Hu14.18) from St. Jude Children's Research Hospital. This antibody is designed for the treatment of newly diagnosed high-risk neuroblastoma, a rare and aggressive childhood cancer. According to the agreement, Renaissance has obtained exclusive rights to develop, manufacture, and commercialize Hu14.18 in key global markets, including the United States, Canada, Europe, China, Japan, and Turkey.
In September 2024, Ligand Pharmaceuticals Inc., a US-based biopharmaceutical company, completed the acquisition of Apeiron Biologics AG for $100 million. Through this acquisition, Ligand gains royalty rights to Qarziba and aims to enhance its commercial royalty portfolio by adding a high-value immunotherapy for high-risk neuroblastoma. This move is expected to drive growth by generating long-term, predictable revenue from a diverse range of key products. Apeiron Biologics AG, based in Austria, is a biotech company specializing in the development of immunotherapies for neuroblastoma.
Major players in the neuroblastoma market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Sartorius AG, Recordati S.p.A, United Therapeutics Corporation, BeiGene Ltd., MacroGenics Inc., Y-mAbs Therapeutics Inc., RedHill Biopharma Ltd., Clarity Pharmaceuticals Ltd., EUSA Pharma (UK) Ltd., US WorldMeds LLC, Healio Inc., Ascentage Pharma, Laboratorio Elea Phoenix S.A, Curis Inc., PersonGen BioTherapeutics (Suzhou) Co. Ltd., Essential Pharma S.A, Cellectar Biosciences Inc., Provectus Biopharmaceuticals Inc.
North America was the largest region in the neuroblastoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuroblastoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Neuroblastoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neuroblastoma market consists of revenues earned by entities by providing services such as diagnosis and imaging, oncology treatment, and stem cell transplants. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuroblastoma market also consists of sales of radiopharmaceuticals, monoclonal antibodies, and diagnostic tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neuroblastoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on neuroblastoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for neuroblastoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neuroblastoma market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product Types: Tablets; Vaccines; Other Product Types
- 2) By Treatment Type: Chemotherapy; Immunotherapy; Other Treatment Types
- 3) By Distribution Channel: Online; Offline
- 4) By End-User: Hospitals; Clinics
- Subsegments:
- 1) By Tablets: Oral Chemotherapy Tablets; Targeted Therapy Tablets
- 2) By Vaccines: Immunotherapy Vaccines; Therapeutic Vaccines
- 3) By Other Product Types: Injectable Drugs; Monoclonal Antibodies; Cell Therapy Products
- Companies Mentioned:Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Sartorius AG; Recordati S.p.A
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Neuroblastoma Market Characteristics
3. Neuroblastoma Market Trends And Strategies
4. Neuroblastoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Neuroblastoma Growth Analysis And Strategic Analysis Framework
- 5.1. Global Neuroblastoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Neuroblastoma Market Growth Rate Analysis
- 5.4. Global Neuroblastoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Neuroblastoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Neuroblastoma Total Addressable Market (TAM)
6. Neuroblastoma Market Segmentation
- 6.1. Global Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tablets
- Vaccines
- Other Product Types
- 6.2. Global Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Chemotherapy
- Immunotherapy
- Other Treatment Types
- 6.3. Global Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Online
- Offline
- 6.4. Global Neuroblastoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- 6.5. Global Neuroblastoma Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Chemotherapy Tablets
- Targeted Therapy Tablets
- 6.6. Global Neuroblastoma Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Immunotherapy Vaccines
- Therapeutic Vaccines
- 6.7. Global Neuroblastoma Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Injectable Drugs
- Monoclonal Antibodies
- Cell Therapy Products
7. Neuroblastoma Market Regional And Country Analysis
- 7.1. Global Neuroblastoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Neuroblastoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Neuroblastoma Market
- 8.1. Asia-Pacific Neuroblastoma Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Neuroblastoma Market
- 9.1. China Neuroblastoma Market Overview
- 9.2. China Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Neuroblastoma Market
- 10.1. India Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Neuroblastoma Market
- 11.1. Japan Neuroblastoma Market Overview
- 11.2. Japan Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Neuroblastoma Market
- 12.1. Australia Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Neuroblastoma Market
- 13.1. Indonesia Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Neuroblastoma Market
- 14.1. South Korea Neuroblastoma Market Overview
- 14.2. South Korea Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Neuroblastoma Market
- 15.1. Western Europe Neuroblastoma Market Overview
- 15.2. Western Europe Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Neuroblastoma Market
- 16.1. UK Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Neuroblastoma Market
- 17.1. Germany Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Neuroblastoma Market
- 18.1. France Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Neuroblastoma Market
- 19.1. Italy Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Neuroblastoma Market
- 20.1. Spain Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Neuroblastoma Market
- 21.1. Eastern Europe Neuroblastoma Market Overview
- 21.2. Eastern Europe Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Neuroblastoma Market
- 22.1. Russia Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Neuroblastoma Market
- 23.1. North America Neuroblastoma Market Overview
- 23.2. North America Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Neuroblastoma Market
- 24.1. USA Neuroblastoma Market Overview
- 24.2. USA Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Neuroblastoma Market
- 25.1. Canada Neuroblastoma Market Overview
- 25.2. Canada Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Neuroblastoma Market
- 26.1. South America Neuroblastoma Market Overview
- 26.2. South America Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Neuroblastoma Market
- 27.1. Brazil Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Neuroblastoma Market
- 28.1. Middle East Neuroblastoma Market Overview
- 28.2. Middle East Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Neuroblastoma Market
- 29.1. Africa Neuroblastoma Market Overview
- 29.2. Africa Neuroblastoma Market, Segmentation By Product Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Neuroblastoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Neuroblastoma Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Neuroblastoma Market Competitive Landscape And Company Profiles
- 30.1. Neuroblastoma Market Competitive Landscape
- 30.2. Neuroblastoma Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sartorius AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Recordati S.p.A Overview, Products and Services, Strategy and Financial Analysis
31. Neuroblastoma Market Other Major And Innovative Companies
- 31.1. United Therapeutics Corporation
- 31.2. BeiGene Ltd.
- 31.3. MacroGenics Inc.
- 31.4. Y-mAbs Therapeutics Inc.
- 31.5. RedHill Biopharma Ltd.
- 31.6. Clarity Pharmaceuticals Ltd.
- 31.7. EUSA Pharma (UK) Ltd.
- 31.8. US WorldMeds LLC
- 31.9. Healio Inc.
- 31.10. Ascentage Pharma
- 31.11. Laboratorio Elea Phoenix S.A
- 31.12. Curis Inc.
- 31.13. PersonGen BioTherapeutics (Suzhou) Co. Ltd.
- 31.14. Essential Pharma S.A
- 31.15. Cellectar Biosciences Inc.
32. Global Neuroblastoma Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Neuroblastoma Market
34. Recent Developments In The Neuroblastoma Market
35. Neuroblastoma Market High Potential Countries, Segments and Strategies
- 35.1 Neuroblastoma Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Neuroblastoma Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Neuroblastoma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
